Back in June, shares jumped 7% over the course of a week after the company received approval to buy medical device maker Synthes for $20 billion, resulting in upgrades from several Wall Street analysts. Since then, shares …

Read More:
10 stocks least addicted to the Fed's QE3 – Weekend Investor …